TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Lipid profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in motor control (Tremor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement in motor control (Ataxia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement in motor control (SARA score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful weaning from immunosuppressive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression level of CTGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on neurocognitive measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage receiving any vaccine after the baseline time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of adolescents becoming up-to-date on all needed immunizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in size of all lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevention of growth in the index lesion and of any new lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in histological grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in muscle strength torque peaks at dinamometer isokinetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscular structure with ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Vascular Endothelial Growth Factor (VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in muscle power test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cellular metabolic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of Periocular Skin Hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Magnitude of total corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving HbA1c Concentration ≤7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With a Documented Discussion of Goals of Care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Tonsillectomy Outcome Inventory -14 (TOI-14) follow-up score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in CAPS-SX Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Durable Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity of ctDNA biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H-reflex suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Withdrawals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Dinner Request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Sysmex infection scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Achievement of Complete Remission (CR) at Reinduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Skin Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LDL-C levels at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Primary Prostate Lesions Detected by mpMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Epithelial permeability to fluorescein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Alcohol Withdrawal Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Diazepam Received (mg)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Dexmedetomidine Received (mg)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: heart rate average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic blood pressure average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing a Grade 3 Immediate Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Serious Adverse Events By Age
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of protein energy wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rehospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: deterioration of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Successfully Completed Telemedicine Visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Participants Experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal Clinical Laboratory Tests
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of D324
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of D324
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of D797
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of D797
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of plasma areas under the curve of coffee phenolics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response 12 weeks post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in cross-sectional area of the patellar tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in Depression Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paediatric HIV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in HAMD-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dressing Durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Strike-through After 7 Days Wear Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death Within 8 Weeks of the Study Cell Infusion
Endpoint domain: Mortality/survival
Primary endpoint: Comparison of EMA (colour scale) images to baseline US grey-scale images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma TTR stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CSF TTR stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Tissue Mean Weighted Glucose (MWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Menopause-Specific Quality of Life (MENQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Westley croup score at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of patients with high ctDNA fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of source of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ethnic and Racial Identity (ERI) development: Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the Plasma concentration versus time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian Timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Procedure Bacteriuria
Endpoint domain: Adverse events/effects
Primary endpoint: Distance walked in 6 minutes after the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressures (DBP/SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase of at Least One Weekly Complete Spontaneous Bowel Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase of at Least Two Weekly Complete Spontaneous Bowel Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mid levels of TDF, 3TC, and EFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of the evolution of AIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant-Murley Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean number of wet nights/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Concentrations to the 7 Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of adherence to isolation measures
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: The incidence of symptoms and their duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area Under the plasma Concentration versus time curve (AUCt) of Edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Texture Index (MTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain assessed by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of genes encoding components of the fibrinolytic system and inflammatory cytokine signalling molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving RVNA titer ≥ 0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants achieving RVNA titer ≥ lower limit of quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer Ratio (GMTR) of RVNA titer (post-/pre-vaccination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of partial replacement of concentrated oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Pain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity of hematological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Morbidity of diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of asthma rescue-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of seasickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of eosinophils in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EEG Power in the frontal polar region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of bimekizumab (BKZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events (AE) from Baseline to Safety Follow Up
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet Aggregation Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in palpebral fissure height (PF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in marginal reflex distance-1 (MRD1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in marginal reflex distance-2 (MRD2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levator function (LF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of FOBT ColoCARE Home kit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ColoCARE Completion Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake at lunch following the snack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary amino acid utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to resolution of fever (<100.40F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative RT-PCR test on day 5 of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Deep Vein Thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of regulatory B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in severity of hemoptysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of auditory skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug levels of lopinavir, ritonavir, raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Atrial Fibrillation lasting six or more minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients achieving target HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of stay in the emergency service
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of chest compressions in CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Responder Rate at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum anti-typhoid fever proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with persistent anti-natalizumab antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With EC-Confirmed CMV Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lesion Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Serum immune globulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of NK cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adequacy of lymph node sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of treatment in Invasive Aspergillosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Basophil activation test value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating βHB levels (mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mucins in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vitamin D (25OHD) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blepharospasm Diagnostic Rating Scale (BDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blepharospasm Severity Rating Scale (BSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blepharospasm Disability Index (BSDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Premature Discontinuation of Study or Study Drug Due to Any Reason
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Marked Abnormalities in Hematology Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Subjects With Marked Abnormalities in Clinical Chemistry Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Number of draining fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline to 90-day Follow-up in Self Reported Weekly Minutes of Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with skin irritation grade >= 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of adverse events experienced by participants
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieved Effective Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time to be symptoms free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy measured by Children's Depression Rating Scale (CDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Ketamine Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive accuracy of miRNA test for endometrial cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Phlebitis or Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ADHD Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous glucose tolerance test (IVGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: skin microflora count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee stability (KT1000 assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pivot shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Reported Pain Relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to initiate second line therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual Performance (LogMar)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Acceptable Mechanical Lens Fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Acceptable Cosmetic Lens Fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk rate of incorrect patient classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Counselor fidelity to Contingency Management Substance Abuse Treatment Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counselor knowledge of Contingency Management Substance Abuse Treatment Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SKAMP score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-dose PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of kidney discard or graft failure
Endpoint domain: Mortality/survival
Primary endpoint: Energy expenditure as determined by metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes